CSA Biotech

CSA Biotech is a clinical-stage biotechnology company focused on the development of Ceragenins, a novel class of synthetic small molecule mimics of endogenous antimicrobial peptides. These compounds, known as Cationic Steroid Antibiotics (CSAs), are designed to provide broad-spectrum activity against bacteria, viruses, and fungi while maintaining stability and low toxicity. The company's lead programs target chronic infections in cystic fibrosis and various topical applications, including wound care and ophthalmology. By leveraging its proprietary platform, CSA Biotech aims to address the growing global threat of antimicrobial resistance through a mechanism of action that physically disrupts microbial membranes.